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ABSTRACT 
A diet rich in fruits and vegetables is associated with a reduced incidence of many 
cancers, including colon cancer. Apigenin is a dietary flavonoid that is widely distributed in 
fruits and vegetables. It was previously shown to induce G2/M cell cycle arrest in three 
different human colon cancer cell lines that have APC mutations (SW 480, HT29 and 
CaCo2). In this study, we assessed the importance of the APC tumor suppressor mutation in 
relation to the ability of apigenin to induce cell cycle arrest. The cell model system utilized 
for this study consisted ofHT29-APC cells, which contain an inducible wild-type APC gene 
characterized by an increase in apoptosis in cultured HT29-APC cells treated with l00µM 
ZnCh. HT29-GAL cells, containing ~-galactosidase plasmid, served as the control. 
Apigenin treatment (from 0µM to 80µM) for 48 hours resulted in a significant (P<0.05) 
reduction in the cell number concurrent with flow cytometry results showing a dose-
dependent accumulation of cells in G2/M phase in both uninduced HT29-APC and HT29-
GAL cells. Terminal Deoxytransferase-Mediated Deoxyuridine NickEnd-Labeling (TUNEL) 
assay determined a significant (P<0.05) increase in the percentage of apoptotic HT29-APC 
cells when treated with 0µM apigenin and lO0µM of ZnCh after 120hr (induction ofwild-
type APC gene). Additionally, apigenin treatment (80µM) appeared to enhance the 
sensitivity of the HT29-APC cells to apoptosis when treated with Zn Ch to induce wild-type 
APC expression. On the other hand, no significant changes in the percentage of apoptotic 
cells were present either in the HT29-APC cells when treated with apigenin alone or in the 
HT29-GAL cells when treated with either apigenin and/or ZnCh. Flow cytometric analysis 
showed an increase (P<0.05) in the percentage of cells in G2/M when HT29-APC cells were 
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treated with 80µM apigenin for 120 hr. This increase was not present in HT29-APC cells 
when treated with both 80µM apigenin and 1 00µM ZnCh for 120hr. Nevertheless, the 
apigenin-treated HT29-GAL cells showed a significant (p<0.05) accumulation of cells in 
G2/M regardless ofthe·presence of ZnCh. These results suggest that APC dysfunction may 
be critical for apigenin to induce cell cycle arrest in human colon cancer cell lines. 
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CHAPTERl.GENERALINTRODUCTION 
Introduction 
Consumption of a diet abundant in fruits and vegetables has been associated with a 
reduced incidence of many cancers, including colon cancer (Slattery et al. 1997). Several 
epidemiological studies have indicated that the higher consumption of fruits and vegetables 
may lower the risk of certain cancers (Williams et al. 1999). Numerous classes of 
compounds present in fruits and vegetables are assumed to take the role of cancer-preventive 
agents (Birt et al. in press, Hill 1999). Among these, one class of compounds may include 
the flavonoids, which are widely distributed among plants. 
Apigenin[5,7,4'-trihydroxyflavone], a common dietary flavonoid, has been found in a 
variety of fruits and vegetables including parsley, onions, apples, tea, and chamomile. Our 
laboratory has previously studied the possible role of apigenin as a chemopreventive agent in 
colon carcinogenesis. Animal studies revealed that colonic ornithine decarboxylase (ODC) 
activity and aberrant crypt foci (ACF) formation in CF-1 mice were reduced with 0.1 % 
dietary apigenin when compared with the control (Au et al. unpublished). Wang et al. (2000) 
has shown that apigenin induced G/M cell cycle arrest in three different colon cancer cell 
lines with truncated APC gene (SW480, HT29, and Caco2). The different effectiveness of 
apigenin on cell growth and cell cycle arrest in these three cell lines was suggested to be 
related, in part, to the different genetic background of these cells. Thus, it lead to the 
implllcation that apigenin may have a stronger effect on tumors with certain genetic 
mutations. 
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The cause of colorectal cancer is now widely accepted to be the accumulation of 
mutations in specific genes controlling cell division, apoptosis and DNA repair. One of the 
early events involved in colorectal tumorigenesis is associated with mutations in or 
inactivation of the adenomatous polyposis coli (APC) tumor suppressor gene. The APC gene 
is presumably involved in a broad spectrum of cellular functions as well as playing a key role 
in the maintanace of homeostasis in continuously proliferating tissues, and preventing 
uncontrolled growth and tumor formation (Kinzler and Vogelstein 1996). It was found to be 
a critical element in the colon cancer pathway as more than 80% of colorectal tumors have 
inactivating APC gene mutations (Goss and Groden 2000). In absence of functional APC, 
free ~-catenin accumulates in the cytoplasm, leading to its translocation to the nucleus. ~-
catenin is a cytoplasmic protein, which has important functions in cellular adhesion and 
development (Morin et al. 1996). It associates with DNA~binding protein T-cell 
transcriptional factors (Tct) and this ~-catenin /Tcf complex may modulate the transcription 
of target genes such as c-myc (He et al. 1998). Activation of the signaling pathway involving 
the proto-oncogene c-myc will lead to the promotion of cell growth and proliferation. c-myc 
expression levels are usually increased in most colorectal cancers and may be linked as a 
direct consequence of mutations of the APC tumor suppressor gene (He et al. 1998). 
Our objective was to test the hypothesis that the APC mutations in human colon 
cancer cell lines are critical for apigenin to induce a G2/M cell cycle arrest and thus affect 
tumor cell growth, whereas the presence of wild-type APC expression would block the 
ability of apigenin to induce cell cycle arrest. To address this hypothesis, we used a unique 
cell model system, consisting oftransfected HT29 (HT29-APC and HT29-GAL) human 
colon cancer cell lines. HT29-APC cells contain an inducible wild-type APC, which was 
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expressed by an increase in the proportion of apoptotic cells following the addition of 1 00µM 
of Zn Ch (Morin et al. 1996). HT29-GAL cells contain a galactosidase plasmid, serving as a 
control cell line. In this study, TUNEL assay was conducted to demonstrate the induction of 
apoptotic cells in the HT29 APC cells treated with Zn Ch. In addition, cell count and flow 
cytometric analysis were assessed concurrently to determine the effectiveness of apigenin on 
cell growth and cell cycle in these cells. 
Thesis Organization 
This thesis contains a general introduction, which includes a literature review, 
followed by a manuscript suitable for publication in a scientific journal, a general conclusion 
and appendix. Literature cited is listed in alphabetical order according to the author's name 
at the end of each chapter. 
Literature Review 
Diet and Colon Cancer 
A diet rich in fruits and vegetables has been associated with a reduced incidence of 
cancers, including colon cancer (Slattery et al. 1997). This association may be due to the fact 
that such diets tend to be lower in energy and fat or to the different components found· in 
fruits and vegetables. Several epidemiological studies have indicated that the higher 
consumption of fruits and vegetables may lower the risk of certain cancers (Williams et al. 
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1999). In a study by Steinmetz et al. (1994), total intake of fruits and vegetables was 
inversely associated with colon cancer risk in women. A similar association was observed 
between fruit and vegetable intake and lung cancer (Steinmetz et al. 1993, Yong et al. 1997), 
where a significant 20 to 60% reduction in lung cancer risk was observed for the high versus 
the low total fruit and vegetable consumption. Other studies conducted in different countries 
have also assessed the association between fruit and vegetable intake with many types of 
cance::rs (Steinmetz and Potter 1996). Because of the complexity of plant foods, numerous 
naturally occurring compounds found in fruits and vegetables may contribute to cancer 
prevention (Birt et al. in press, Hill 1999). Among these compounds, one class is the 
flavonoids, which are widely distributed among plants. Flavonoids are plant secondary 
metabolites, composed of a common structure (C6-C3-C6) with one or more hydroxyl 
substituents. The average daily human intake of flavonoids in the UK and in USA has been 
estimated to be 20mg to one gram (Hollman and Katan 1999). Recent studies have 
investigated the potential mechanisms by which these agents may prevent cancer, which 
include their ability to control cell cycle, and thus inhibiting aberrant cell proliferation (Birt 
et al. in press). Compelling data have shown the effect of flavonoids on cell growth and cell 
cycle. Flavonoids such as quercetin have been found to induce apoptosis at concentrations of 
50µM or higher in several cancer cell lines (Wei et al. 1994). Furthermore, quercetin 
treatment was found to be effective in preventing skin carcinogenesis in the two-stage model 
ofDMBA-initiated and TPA-promoted cancer, as well as inhibiting azoxymethanol (AOM)-
induced aberrant crypt foci (ACF) in animal models (Deschner et al. 1991). Other 
compounds such as genistein, an isoflavonoid, was shown to induce cell cycle arrest at G2/M 
in HGC-27 human gastric cancer cells at doses up to 60 µM (Matsukawa et al. 1993). 
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Apigenin [5,7,4'-trihydroxyflavone], a common dietary flavonoid (see Figure 1), is 
widely distributed in a variety of fruits and vegetables including parsley, onions, apples, tea, 
and chamomile. It is relatively nontoxic and nonmutagenic when compared with other 
flavonoids such as quercetin (Brown and Dietrich 1979). Sato et al. (1994) demonstrated the 
induction of G2/M cell cycle arrest by apigenin in rat neuronal cells. Apigenin was also 
shown to inhibit cell growth in solid malignant tumor cells (Fotsis et al. 1997), and in 
leukemia cells (Lee et al. 1995). It has been studied extensively in the Birt laboratory as a 
potential chemopreventive agent for skin cancer, both in vivo and in vitro. Wei et al. (1990) 
has shown that apigenin significantly inhibited epidermal ornithine decarboxylase (ODC) 
activity induced by 12-0-tetradecanoylphorbol-13-acetate (TP A) in murine epidermis. 
Topical application of apigenin significantly reduced the number of benign papillomas and 
squamous cell carcinomas in Sencar mice when treated in the two-stage skin carcinogenesis 
model initiated by 7, 12-dimethylbenz(a)anthracene (DMBA) and promoted by 12-0-
tetradecanoylphorbol-13-acetate (TP A). Based on these studies demonstrating the 
chemopreventive effects of apigenin in vivo, in vitro studies were conducted to investigate 
the molecular mechanisms of apigenin's chemopreventive avtivities. Cell culture studies by 
Lepley et al. ( 1996) demonstrated that apigenin treatment at doses up to 45 µM resulted in the 
induction of a G2/M cell cycle arrest in C50 murine keratinocyte cell line. The cellular 
conc<!ntrations detected in these apigenin-treated C50 cultured cells were similar to the 
concentrations revealed in the in vivo mouse epidermal cells treated topically with 5 µM 
apigenin (Li et al. 1996). Because some flavonoids may induce apoptosis, the possibility of 
apigenin induction of apoptosis at high doses was investigated in keratinocytes (Lepley et al. 
1997). However, they were unable to detect apoptosis determined by DNA fragmentation 
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gels, TUNEL or flow cytometry. These promising results demonstrating the effectiveness 
of apigenin in the prevention of skin cancer have prompted further studies to investigate the 
efficacy of apigenin, through a dietary approach, on chemoprevention of colon 
carcinogenesis. 
OH 
HO 0 
OH 0 
APIGENIN (5, 7, 4'-trihydroxyflavone) 
Figure 1. Structure of Apigenin 
Recent studies in the Birt laboratory have investigated the possible role of apigenin as 
a chemopreventive agent in colon carcinogenesis. In animal studies, 0.1 % dietary apigenin 
reduced the colonic omithine decarboxylase (ODC) activity and aberrant crypt foci (ACF) 
formation in CF-1 mice when compared with the control (Au et al. unpublished data). The 
measurement of the ODC activity, which is a marker for cell proliferation, along with the 
development of ACF, which are early preneoplastic lesions in colonic mucosa of carcinogen-
treated animals, are markers that have been developed and extensively used to study colon 
carcinogenesis. In vitro studies have shown that apigenin induced G2/M cell cycle arrest in 
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three different colon cancer cell lines (SW480, HT29, and Caco2) with truncated APC gene 
(Wang et al. 2000). The apigenin-induced cell cycle arrest was reported to be reversible in 
the colon cancer cells, indicating that the effect of apigenin appeared to be cytostatic rather 
than cytotoxic. The mechanisms by which apigenin induces a G2/M cell cycle arrest were 
also determined in colon cancer cells (Wang et al. 2000), as the association of p34 cdc2 
kinase with cyclin B is required for regulation and activation of cell passage through G2/M 
following a series of phosphorylation and dephosphorylation events (see Figure 2). 
Preparation 
for cell division 
Cvclin A/cdk2 
DNA Replication 
Mitosis 
Figure 2. Major Events in Cell Cycle 
Cyclin D 
cdk2.4.5.6 
Rapid Growth 
Cvclin E/cdk2 
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Apigenin treatment resulted in an inhibition of both p34 cdc2 kinase activity and a 
decrease in cyclin B protein levels. Therefore, these findings suggest that apigenin may act 
as a chemopreventive agent by blocking aberrant cell cycle and proliferation. Moreover, 
apigenin treatment (80µM) for 48 hr effectively blocked the cell cycle at G2/M in SW 480 
cells (64% of cells in G2/M), while having a more modest effect in the HT29 (42%) and 
Caco2 (26%) cells. The different effectiveness of apigeniri on cell growth and cell cycle 
arrest in these three cell lines was suggested to be related, in part, to the different genetic 
background of these cells. Thus, it lead to the implication that apigenin may have a stronger 
effect on tumors with certain genetic mutations, while having limited effects in cells with 
wild-type genes. 
Colon Cancer 
Carcinogenesis is characterized by the loss of normal control and the loss of a balance 
of proliferation, maturation and apoptosis in cells (Kinzler and Vogelstein 1996)( see Figure 
3). Initiation of carcinogenesis may be triggered by DNA damage in the cells, resulting in 
gene mutations unless the genetic damage is corrected. These mutations may affect two 
types of genes that are involved in cellular growth and differentiation: oncogenes and tumor 
suppressor genes (Kinzler and Vogelstein 1996). Oncogenes are mutated versions of normal 
cellular genes (proto-oncogenes) that regulate proliferation and differentiation pathways 
(Allen 1995). Expression of an oncogene results in gain-of-function in a cellular process, 
enhancing cell proliferation or facilitating apoptosis, such as cHaRas (Allen 1995). On the 
other hand, tumor suppressor genes such as adenomatous polyposis coli (APC) or p53 
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typically inhibit cellular proliferation. Mutations of the tumor suppressor genes, resulting in 
a loss in the regulated growth inhibition, will facilitate and enhance proliferation (Morin et al. 
1996). Studies have also determined another type of gene involved in carcinogenesis: DNA-
damage genes. These genes are involved in the repair of damage in order to maintain the 
integrity of the genome. Mutations in these genes may lead to genetic instability, which are 
also found in many tumors (Allen 1995). 
APC Ras p53 
Mutation Mutation Mutation 
i i I Carcinol Normal Early Late Epitheliu Adenoma Adenoma 
Figure 3. Voge/stein Model of Colon Carcinogenesis 
The primary functional cell of the intestinal mucosa is the enterocyte. It is produced 
by a stem cell in the colonic crypt and migrates (when mature) towards the top of the crypt 
(Goss and Groden 2000). There, it reaches senescence and is shed into the lumen of the 
bowel. An imbalance in the homeostasis between proliferation and apoptosis of the 
enterocytes can result in colon carcinogenesis. Pathological outgrowths of normal 
developing colonic crypts give rise to the formation of polyps (White 1997). Adenomatous 
polyps are precursors of colon carcinomas. This relationship was established by studies of an 
inherited disorder, Familial Adenomatous Polyposis (F AP) (Su et al. 1992). F AP is an 
autosomal-dominant precancerous condition characterized by the appearance of hundreds to 
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thousands of adenomatous polyps throughout the entire colorectum. The disease is caused by 
a germline mutation in the APC tumor suppressor gene localized on chromosome 5q21 
(Kinzler and Vogelstein 1996). If left untreated, these polyps would give rise to one or more 
colorectal carcinomas by the third or fourth decade of life (White 1999). 
The fundamental cause of colorectal cancer resides in alterations or mutations of 
genes involved in cellular growth and differentiation (Kinzler and Vogelstein 1996). During 
the development of colorectal cancer, one of the early events involved in colorectal 
tumorigenesis is associated with mutations in or inactivation of the adenomatous polyposis 
coli (APC) tumor suppressor gene. The APC gene is presumably involved in a broad 
spectrum of cellular functions as well as playing a key role in the maintanace of homeostasis 
in continuously proliferating tissues, and preventing uncontrolled growth and tumor 
formation (Kinzler and Vogelstein 1996). APC gene, isolated in 1991, was localized to 
human chromosome 5q21 and encodes for a large protein of 2,843 amino acids (Kinzler et al. 
1991). It contains 16 exons (15 coding and 1 non-coding), the largest (exon 15) containing 
over 75% of the 8,535 base pairs of coding sequence. Exon 15 is the target of most germline 
mutations in FAP and somatic mutations in tumors (Nishisho et al. 1991). An important 
function of the APC protein is to regulate free ~-catenin level through the cooperation with 
glycogen synthase kinase 3~ (GSK-3~) (Kinzler and Vogelstein 1996). ~-catenin is a 
cytoplasmic protein, which has important functions in cellular adhesion and development. ~-
catenin is associated with cadherins, which are transmembrane proteins responsible for cell-
cell interactions of the epithelial cells (Su et al. 1993). The APC protein contains a unique 
motif for ~-catenin binding, consisting of a 15-amino acid sequence binding sites (Su et al. 
1993). Moreover, the APC also contain 20-amino acid sequence repeats, which require 
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phosphorylation by (GSK3f3) in order to bind ~-catenin (Rubeinfeld et al. 1996). When free 
f3-catenin levels are high in the cytoplasm, GSK3 associates with the APC-P-catenin 
complex, forming a multi-protein complex (Kinzler and Vogelstein 1996). ~-catenin is then 
phosphorylated, which leads to its disassociation from the complex and its degradation 
through an ubiquitin-dependant proteasomal pathway (Aberle et al. 1997). Together, these 
observations suggest that APC and GSK3~ may function together to control ~-catenin levels 
in the cytoplasm (see Figure 4). 
APC appears to be a unique microtubule associated protein, as it has one domain that 
directly binds to the microtubules involved in cell migration (Mimori-Kiyosue 2000). It 
moves along the microtubules and concentrates on their growing ends, actively contributing 
to the assembly and reorganization of the microtubule networking. An adjacent binding 
domain on the APC protein binds to EB 1, a member of the family of tubulin-binding proteins 
that interact with the microtubules (Su et al. 1995). These findings suggest that APC is 
involved in the process of cell migration and_ cell division. APC may also play an important 
role in regulating cell adhesion. As mentioned before, APC binds and regulates f3-catenin, an 
intracellular protein involved in cell-cell adhesion between epithelial cells through 
interactions with cadherins (Su et al. 1993). APC does not directly associate with the 
cadherins, but only through association with P-catenin proteins. 
APC and ~-catenin are involved in the wnt-1 signaling pathway (Akiyama 2000) 
(Figure 4). The wnt-1 protein is involved in growth and developmental signaling pathways 
in cells. When wnt-1 binds to its transmembrane receptor frizzled, it activates a signal 
transduction pathway involving a protein called disheveled ( dsh), which impacts negatively 
on GSK3~ (Goss and Groden 2000). Repression of GSK3~ will cause the inability of APC 
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to bind to ~-catenin, resulting in the repression of cytoplasmic ~-catenin degradation. 
Therefore, the major outcome of wnt-1 signaling is the stabilization of ~-catenin and its 
accumulation in the cytoplasm. 
APC gene was found to be a critical element in the colon cancer pathway as more 
than 80% of colorectal tumors have inactivating APC gene mutations (Goss and Groden 
2000). APC mutations lead to the formation of an adenoma, which are precursors of 
carcinomas as they are formed as pathologic outgrowths of a normal developing colonic 
crypt (K.inzler and Vogelstein 1996, White 1999). Most mutations found in the APC gene 
are either frameshift mutations or nonsense point mutations (Laurent-Puig et al. 1998, 
Nagase and Nakamura 1993). Most of these mutations lead to a stop codon in the APC 
reading frame, resulting in the premature termination of the polypeptide chain and the 
production of a truncated protein (Kinzler and Vogelstein 1996). In the absence of functional 
APC, the wnt-1 pathway is turned on (Akiyama 2000). As mentioned earlier, the activation 
of wnt-1 leads to the accumulation of free ~-catenin in the cytoplasm. Free ~-catenin is 
translocated to the nucleus where it associates with the T-cell transcriptional factors (Tcf) or 
lymphoid enhancer factor (Lef) transcription factors. The ~-catenin /Tcf or Lef complex may 
modulate the transcription of Tcf/Lef-regulated target gene expressiot;1., such as c-myc. (He et 
al. 1998). 
The c-myc proto-oncogene is a member of the myc family of genes, which are 
assumed to be involved in the regulation of cell proliferation, differentiation and apoptosis 
(Fearon and Vogelstein 1990). The c-myc induction of either the apoptotic pathway or the 
proliferative pathway is dependent upon the correspo1:ding signaling of survival factors or 
cell death factors (Yokota et al. 1986). Only those cells receiving the appropriate survival 
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signaling would continue to grow and undergo c-myc-induced cell proliferation. The c-myc-
induced apoptotic pathway is activated through a single genetic lesion in cells, resulting in 
apoptosis instead of proliferation. However, deregulation of the c-myc expression, leading to 
uncontrolled cell proliferation, was found in 60% to 80% of the human colorectal cancers 
(Goh et al. 1996). He et al. (1998) explained this phenomenon through studies involving the 
identification of cancer-promoting genes at the end of the wnt-1 pathway. c-myc was 
Cytosol 
Degraded f3-cat 
Figure 4. APC in Normal Cells 
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identified as one of the Tcf-regulated genes involved in the wnt-1 signaling pathway, as they 
found that c-myc expression was strongly suppressed by the induction of wild-type APC 
expression. Their findings suggest that the APC protein may regulate c-myc expression 
through modulating P-catenin levels, thus controlling the P-catenin/Tcf target c-myc gene 
transcription. 
Colon Cancer Models 
The study of colon carcinogenesis involves the application of a wide variety of model 
systems, thus includes cell culture and animal models. Many animal models have been 
developed to simulate the conditions of various human diseases. Reliable animal models are 
critical as they are valuable in understanding human diseases. An example can be given by 
the azoxymethane (AOM) model system. AOM is a potent inducer of carcinomas of the 
large intestine in various strains of male and female rats (Reddy and Maruyama 1986). The 
AOM treatment induces colon tumors predominantely in the distal colon, which is similar to 
the-distribution of tumors in the human colon (Holt et al. 1996). Additionally, as described 
below, mutations induced by AOM treatment are similar to the mutations found in human 
colon tumors. Mutations in the tumor suppressor gene APC are known to be early events in 
the colon cancer process in humans. Studies by Maltzman et al. (1997) demonstrated that 
AOM-induced mouse colon adenomas and adenocarcinomas did not express full-length APC 
proteins,in agreement with observations in human colon carcinogenesis. Other mutations 
induced by AOM treatment in rodents similar to human colon tumors also include ras 
oncogene mutations (at codon 12 ofK- and H-ras) (Singh et al. 1994). 
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Transgenic animal models such as the multiple intestinal neoplasia (Min) mouse 
model were also developed and are used predominantly to study the relationship between the 
nutritional factors and colon carcinogenesis. The Min mouse carries a fully penetrated 
dominant mutation at codon 850 of the murine APC gene, resulting in a truncated APC 
protein (Su et al. 1992). Several studies using Min mice demonstrated that ~97% of tumors 
were found in the small intestine and ~3% of the tumors were in the colon, all the tumors 
being adenomas (Jacoby et al. 1996). Although the Min mice have an autosomal dominant 
inherited predisposition to develop numerous intestinal tumors, it appears that the phenotypic 
expression of APC mutations in the Min mouse is somewhat different from human colon 
cancer. Patients with Familial Adenomatous Polyposis (F AP) develop adenomas found 
exclusively in the colon and some in the duodenum, whereas the Min mouse develop the 
majority of the adenomas in the small intestine (Su et al. 1992). 
The animal models mentioned above are useful in understanding the relationship 
between nutritional factors and colon cancer. The identification of the mechanisms where 
diet may alter cancer is important in optimizing intakes of foods and nutrients for cancer 
prevention in animals and later in the application to human diets. Therefore, results from 
studies using both genetic based and chemically-induced models may contribute significantly 
to many aspects in the understanding of genetics and nutritional factors in relation to colon 
carcinogenesis. However, the integration of cell culture studies and experimental animal 
studies would provide a much better understanding in the relationship between nutrition and 
cancer. Many cell model systems are presently used to solve enigmatic events in 
carcinogenesis, and to determine the mechanisms behind the modulation of dietary factors in 
cancer prevention. Cell culture studies involving different cancer cell lines help contribute to 
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the simulation and better optimization of certain physiological conditions. In addition, the 
application of a particular cell model system may prove useful as a basis for testing the 
hypothesis of a particular study. For example, the development of a particular cell model 
system involving transfected human colon cancer cell lines, allow the induction of exogenous 
factors, which may mimic a "normal" cellular environment. An example of the application 
of this particular cell model system will be presented further on in this present study. 
HT29-APC and HT29-GAL Cell Culture Model 
In this study, we used the cell model system consisted of transfected HT29 cells (HT29-
APC and HT29-GAL ), which proved useful as we aimed to determine the impact of the APC 
tumor suppressor gene on the effectiveness of apigenin to inhibit tumor cell growth. The 
HT29 is a human colon cancer cell line that contains APC mutations, p53 gene mutations and 
wild-type ras (Huang et al. 1994). The transfected HT29-APC contains a ZnCh-inducible 
APC gene under control of the metallothionine promoter, whereas the HT29-GAL cells, 
containing ~-galactosidase plasmid, served as the control (Morin et al., 1996). Previous 
studies by Morin et al. (1996) demonstrated that the expression of the wild-type APC in the 
HT29-APC cells (following ZnCh treatment) induced an increase in apoptosis determined by 
TUNEL assay. Western blot analysis determined the expression of full-length APC protein 
in the HT29-APC cells after they were treated with l00µM of ZnCh (Morin et al. 1996). It 
was proposed by He et al. (1998) that the APC protein prevented ~-catenin from forming a 
complex with Tcf-4, which consequently supresses c-myc transcription. As mentioned 
earlier, the over-expression of c-myc accompanied by uncontrolled proliferation in the 
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colonic tumor cells was suppressed in the HT29-APC cells expressing full-length APC 
protein following ZnCh treatment (He et al. 1998). 
Hypothesis 
The hypothesis of this present study was that apigenin would induce a G2/M cell 
cycle arrest in colon cancer cells with APC mutations. We proposed that apigenin would be 
more effective in cellular growth inhibition in the zinc-treated HT29-GAL cells than in the 
zinc-treated HT29-APC cells, since the HT29-GAL cells do not express the wild-type APC 
following ZnCh treatment. Cell growth inhibition in the HT29-GAL cells was hypothesized 
to be due to the apigenin-induced G2/M cell cycle arrest. On the other hand, we believe that 
the wild-type APC expression (following ZnCh treatment) in the HT29-APC cells would 
prevent apigenin-induction of G2/M cell cycle arrest. The HT29-APC cells would also show 
a decrease in cell number upon treatment with apigenin and ZnCh. However, the decrease in 
cell number would be due to the expected increase in apoptosis following ZnCh treatment 
(induction of wild-type APC expression). 
Objective 
Our main objective is to test our hypothesis utilizing the cell model system involving 
transfected HT29 (HT29-APC and HT29-GAL) cells described earlier. Cell growth, as well 
as flow cytometry results, revealed the effect of apigenin on cell proliferation and cell cycle. 
TUNEL assay was conducted to demonstrate the induction of apoptotic cells following ZnCh 
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treatment (induction of wild-type APC) in HT29-APC cells. The ability to restore the 
expression of the wild-type APC in the HT29-APC cells (following ZnCh treatment) allowed 
us to investigate the importance of the APC mutations found in human cancer cells for 
apigenin-induced G2/M cell cycle arrest. However, the induction of the wild-type APC 
expression in the ZnCh-induced HT29-APC cells did not correct the other existing mutations 
(the APC and p53 mutations), as these cells are derived from the HT29 colon cancer cells. 
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CHAPTER 2. IMPACT OF ADENOMATOUS POLYPOSIS COLI (APC) TUMOR 
SUPRESSOR GENE IN HUMAN COLON CANCER CELL LINES ON CELL 
CYCLE ARREST BY APIGENIN 
A paper to be submitted to the journal Carcinogenesis 
C. S. Chung, D. Cheng, D. F. Birt 
Abstract 
Apigenin is a dietary flavonoid that is widely distributed in fruits and vegetables. It 
was previously shown to induce G2/M cell cycle arrest in three different human colon cancer 
cell lines that have APC mutations (SW 480, HT29 and CaCo2). The research reported here 
assessed the importance of the APC tumor suppressor mutation in relation to the ability of 
apigenin to induce cell cycle arrest. The cell model system utilized for this study consisted 
ofHT29-APC cells, which contain an inducible wild-type APC gene under control of the 
metallothionine promoter. Induced wild-type APC expression was characterized by an 
increase in apoptosis in cultured HT29-APC cells treated with 1 00µM Zn Ch. HT29-GAL 
cells, containing ~-galactosidase plasmid, served as the control. Treatment with apigenin 
alone (from 0µM to 80µM) for 48 hours resulted in a significant (P<0.05) reduction in the 
cell number concurrent with flow cytometry results showing a dose-dependent accumulation 
of cells in G2/M phase in both uninduced HT29-APC and HT29-GAL cells. Upon induction 
of the APC gene in HT29-APC cells, TerminalDeoxytransferase-Mediated Deoxyuridine 
NickEnd-Labeling (TUNEL) assay results showed that the percentage of apoptotic HT29-
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APC cells treated with 1 00µM of ZnCh and 0µM apigenin increased significantly (P<0.05) 
after 120hr treatment. Additionally, apigenin treatment (80µM) appeared to enhance the 
sensitivity of the HT29-APC cells to apoptosis when treated with Zn Ch to induce wild-type 
APC expression. On the other hand, no significant changes in the percentage of apoptotic 
cells were present either in the HT29-APC cells when treated with apigenin alone or in the 
HT29-GAL cells when treated with either apigenin and/or ZnCh. Flow cytometric analysis 
showed an increase (P<0.05) in the percentage of cells in G2/M when HT29-APC cells were 
treated ~ith 80µM apigenin for 120 hr. This increase was not present in HT29-APC cells 
when treated with both 80µM apigenin and l00µM ZnCh for 120hr. Nevertheless, the 
apigenin-treated HT29-GAL cells showed a significant (p<0.05) accumulation of cells in 
G2/M regardless of the presence of Zn Ch. These results suggest that APC dysfunction may 
be critical for apigenin to induce cell cycle arrest in human colon cancer cell lines. 
Introduction 
A diet rich in fruits and vegetables has been associated with a reduced incidence of 
cancers, including colon cancer (Slattery et al. 1997). Several epidemiological studies have 
indicated that the higher consumption of fruits and vegetables may lower the risk of certain 
cancers (Williams et al. 1999). Numerous classes of compounds present in fruits and 
vegetables are assumed to take the role of cancer-preventive agents (Birt et al. in press, Hill 
1999). Among these, one class of compounds includes the flavonoids, which are widely 
distributed among plants. Apigenin [5,7,4'-trihydroxyflavone], a common dietary flavonoid, 
has been found in a variety of fruits and vegetables including parsley, onions, apples, tea, and 
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chamomile. It has been shown to induce cell cycle arrest in both epidermal and fibroblast 
cells (Lepley et al. 1996), and to inhibit skin tumorigenesis in murine model (Wei et al. 
1990). 
Our laboratory has previously studied the possible role of apigenin as a 
chemopreventive agent in colon carcinogenesis. Animal studies revealed that colonic ODC 
activity and ACF formation in CF-1 mice were reduced with 0.1 % dietary apigenin when 
compared with the control (Au, et al. unpublished). Wang et al. (2000) has shown that 
apigenin induced Gi/M cell cycle arrest in three different colon cancer cell lines with 
truncated APC genes (SW480, HT29, and Caco2). The different effectiveness of apigenin on 
cell growth and cell cycle arrest in these three cell lines was suggested to be related, in part, 
to the different genetic background of these cells. Thus, it lead to the implication that 
apigenin may have a stronger effect on tumors with certain genetic mutations. 
The cause of colorectal cancer is now widely accepted to be the accumulation of 
mutations in specific genes controlling cell division, apoptosis and DNA repair. One of the 
early events involved in colorectal tumorigenesis is associated with mutations in or 
inactivation of the adenomatous polyposis coli (APC) tumor suppressor gene. The APC gene 
is presumably involved in a broad spectrum of cellular functions as well as playing a key role 
in the maintanace of homeostasis in continuously proliferating tissues, and preventing 
uncontrolled growth and tumor formation (Kinzler and Vogelstein 1996). It was found to be 
a critical element in the colon cancer pathway as more than 80% of colorectal tumors have 
inactivating APC gene mutations (Goss and Groden 2000). In the absence of functional 
APC, free ~-catenin accumulates in the cytoplasm, leading to its translocation to the nucleus. 
~-catenin is a cytoplasmic protein, which has important functions in cellular adhesion and 
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development (Morin et al. 1996). It associates with DNA-binding protein T-cell 
transcriptional factors (Tcf) and this ~-catenin /Tcf complex may modulate the transcription 
of target genes such as c-myc (He et al. 1998). Activation of the signaling pathway involving 
the proto-oncogene c-myc will lead to the promotion cell growth and proliferation. c-myc 
expression levels are usually increased in most colorectal cancers and may be linked as a 
direct consequence of mutations of the APC tumor suppressor gene (He et al.1998). 
To address the hypothesis that APC mutations are critical for apigenin to induce a 
G2/M cell cycle arrest in human colon cancer cell lines, a unique cell model system was used, 
consisting oftransfected HT29 (HT29-APC and HT29-GAL) human colon cancer cell lines. 
The HT29 cells are known to have APC gene mutations (:frameshift or nonsense point 
mutations) on chromosome 5q21 (Kinzler and Vogelstein 1996), in addition to a mutated p53 
gene and a wild-type ras gene (Huang et al. 1994). Transfected HT29-APC cells contain an 
inducible wild-type APC gene following addition of 1 00µM Zn Cb. This concentration of 
ZnCh was previously shown by Morin et al. (1996) to induce wild-type APC expression in 
the HT29-APC cells determined by Western Blot analysis detecting full-length APC protein 
in the HT29-APC cells following ZnCh treatment. The wild-type APC expression in HT29-
APC cells (following addition of l00µM ZnCh) was manifested by an increase in apoptosis 
determined by TUNEL assay (Morin et al. 1996). On the other hand, transfected HT29-GAL 
cells contain a galactosidase plasmid, serving as a control cell line. We performed TUNEL 
assay to determine the induction of apoptosis following ZnCh treatment in apigenin-treated 
cells. In addition, cell count and flow cytometric analysis were performed to investigate the 
influence of apigenin on cell growth and cell cycle in these cells. 
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Materials and Methods 
Cell Number and Cell Growth 
HT29-APC and HT29-GAL cells were obtained from Dr. Bert Vogelstein's 
laboratory (Morin et al. 1996). Cells were cultured in McCoy's 5A Modified Media (Sigma) 
with 10% Fetal Bovine Serum. They were maintained in an incubator at 37°C with 95% 
atmospheric 0 2 and 5% CO2• Cells were plated and treated when they reached 50-60% 
confluency. 
For cell growth, cells were treated with different doses of apigenin and in the 
presence or absence of 1 00µM of Zn Ch. Cells were harvested ( at time points indicated in 
the results) by trypsinization for 10 minutes. The number of cells was counted with a 
hemacytometer. All four 1-mm comer squares of the hemacytometer were counted and the 
average was calculated. 
Cell Cycle Analysis 
Cells were treated with apigenin and/or with ZnCh (l00µM) and harvested by 
trypsinization. Cells were fixed in 70% ethanol and stored at 4 °C overnight. Fixed cells 
were prepared for flow cytometry analysis by washing twice with Phosphate Buffer Saline 
Solution (PBS), pH 7.4. Cells were resuspended in propidium iodide (20-mg/ml) staining 
solution containing lµg/ml RNase in 10 mM PBS, pH 7.45 and incubated at 37 °C for 30 
minutes. Flow cytometry analysis was performed with a F ACStar-plus flow cytometer 
(Becton Dickinson) with an excitation at 488 nm and an emission at 630 nm. 
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Terminal Deoxytransferase~Mediated Deoxyuridine Nick.End-Labeling (TUNEL) Assay 
Cells were cultured in the presence or absence of 1 00µM Zn Ch along with apigenin 
treatment at 0µM and 80µM. Cells were harvested by trypsinization following 0, 48 and 120 
hours of treatment. Cells were initially fixed for 30 min using 1 % paraformaldehyde, 
followed by secondary fixation in 70% (v/v) ethanol and stored at -20°C overnight. Fixed 
cells were then prepared for TUNEL assay analysis using the APO-BRDU™ Kit 
(Pharmigen). This involved incubating the cells initially in DNA labeling solution for 1hr 
followed by 30 min-incubation periods with the Antibody Solution and PI!Rnase A Solution. 
Stained cells were then analyzed by flow cytometry with a F ACS tar-plus flow cytometer 
(Becton Dickinson) with an excitation at 488 nm and an emission at 630 nm. 
Statistics 
Results were evaluated by one-way analysis of variance (ANOV A) followed by 
Tukey's multiple comparison test using the SPSS (Version 10.0) statistical program. 
Comparisons across cell lines were analyzed by comparing individual means using Student's 
t-test. Data including treatments with apigenin and zinc from HT29-APC were analyzed 
separately from HT29-GAL, using analysis of variance (ANOVA) followed by Tukey's 
multiple comparison test. 
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Results 
Impact of Apigenin on Cell Growth and Cell Cycle in Uninduced Cells 
Treatment of the HT29-APC and HT29-GAL cells with apigenin doses up to 80µM 
resulted in a dose-dependent decrease in cell number compared to the vehicle control (Figure 
1). Apigenin treatment at 60 and 80µM for 48 hours significantly (p<0.05) decreased in the 
number of both HT29-APC and HT29-GAL cells. Both HT29-APC and HT29-GAL cells 
showed a significant (p<0.05) increase of cells in the G2/M phase by flow cytometric analysis 
after apigenin treatment at 80µM for 48 hours (Figure 2). The decrease in the percentage of 
cells in Gl phase at 60 and 80µM apigenin treatment (p<0.05) was associated with the 
increase in the percentage of cells in the G2/M phase. The percentage of cells in S phase did 
not change with apigenin treatment. 
Impact of Apigenin on Cell Growth and Cell Cycle Arrest in Induced Cells 
The 0µM apigenin-treated HT29-GAL cells showed a significant (p<0.05) increase in 
cell number at 120hr treatment (Figure 3). This increase was also observed in the HT29-
GAL cells when incubated with ZnCh. On the other hand, the HT29-APC cells did not show 
a significant increase in cell number when treated with ZnCh compared to the significant 
(p<0.05) increase when treated with 0µM apigenin for 120 hours. Both cell lines showed a 
significant (p<0.05) decrease in cell number when treated with apigenin alone (80µM) for 48 
and 120 hours. However, the decrease in cell number with treatment at 80µM 
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apigenin+ 1 00µM Zn Ch was more striking than the decrease in HT29-GAL cells treated with 
80µM apigenin+ 1 00µM ZnCh over time (P<0.03). 
Flow cytometric analysis was assessed for cells treated with either apigenin alone or 
in the presence of I00µM ZnCh. The HT29-APC cells showed a significant accumulation of 
cells at G2/M after treatment of 80µM apigenin for 48 and 120 hours. However, when 
treated with ZnCh, the HT29-APC cells did not show an increase in cells in G2/M with 
80µM apigenin (Figure 4). In contrast, the HT29-GAL cells showed a significant 
accumulation of cells in G2/M phase after apigenin treatment regardless of the presence of 
ZnCh. 
Induction of Apoptosis (upon addition of ZnCh) on Apigenin-Treated HT29-APC and 
HT29-GAL cells 
The HT29-GAL cells treated with either apigenin and/or ZnCh did not show a 
significant change in the percentage of apoptotic cells (Figure 5). Treatment of HT29-APC 
cells with 1 00µM of Zn Ch in the presence or absence of apigenin resulted in a significant 
increase in the percentage of apoptotic cells (suggesting the wild-type APC expression). The 
percentage of apoptotic HT29-APC cells treated with 0µM apigenin + I00µM ofZnCh 
increased significantly after 48 and 120hr (refer to Appendix of example ofTUNEL assay · 
results). Interestingly, treatment ofHT29-APC cells with 80µM apigenin + I00µM of ZnCh 
resulted in a more pronounced increase of apoptotic cells (p<0.05) compared to 0µM 
apigenin + 1 00µM of ZnClz treatment. 
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Discussion 
Several epidemiological studies have found that a diet with abundant fruits and 
vegetables is strongly correlated to a reduced risk of cancers (Williams et al. 1999). 
Suggested dietary constituents have included a variety of compounds, including the 
flavonoids. Apigenin, a plant flavonoid, has been a main focus in our laboratory as a 
potential agent for chemoprevention of colon carcinogenesis, both in vivo and in vitro. 
Previous studies in our laboratory have suggested that apigenin may have a stronger effect on 
tumors with certain genetic mutations (Wang et al. 2000). This present study investigated the 
efficacy of apigenin on colon cancer cell lines with different mutational spectra using 
transfected HT29 (HT29-APC and HT29-GAL) human colon cancer cells. HT29-APC cells 
contain an inducible APC gene, and the HT29-GAL cells served as the control. In order to 
assess an expected outcome of APC expression in the HT29-APC cells, we performed the 
TUNEL assay following treatment of cells with 1 00µM of Zn Ch. Our results showed that 
the presence of l00µM ofZnCh increased apoptosis in HT29-APC cells, while the HT29-
GAL cells demonstrated no change in response to zinc treatment. These observations were 
in agreement with Morin et al. (1996) that an increase in apoptotic cells (determined by 
TUNEL assay) was revealed in zinc-induced HT29-APC cells, suggesting the expression of 
APC. 
Apigenin treatment had a strong growth inhibitory effect on both HT29-APC and 
HT29-GAL. As expected, both cell lines showed a significant decrease in cell growth after 
apigenin treatment for 48 hours, which may be correlated with the apigenin-induced G2/M 
cell cycle arrest. These results were consistent with previous observations by Wang et al. 
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(2000) in which apigenin inhibited the growth of three different colonic carcinoma cell lines 
by blocking the cell cycle at 0 2/M phase. The three different cell lines all had APC 
mutations, consistent with the cell lines used in the present study. Since the transfected 
HT29-APC and HT29-GAL cells are derived from the HT29 colorectal cancer cell line, they 
contain APC gene mutations (frameshift or nonsense point mutations) on chromosome 5q21 
(K.inzler and Vogelstein 1996), in addition to a mutated p53 gene and a wild-type ras gene 
(Huang et al. 1994). As a consequence, the induction of the wild-type APC gene (following 
ZnCh treatment) in HT29-APC did not correct the APC or p53 mutations present in the 
HT29 colorectal cancer cell line. However, the presence of wild-type APC following Zn Ch 
treatment presumably restored normal APC function and prevented apigenin induction of 
G2/M cell cycle arrest in the HT29-APC cells. In contrast, in the presence of ZnCh, apigenin 
induced a 0 2/M cell cycle arrest in the HT29-GAL control cells. As mentioned before, the 
presence of ZnCh induces wild-type APC expression in the HT29-APC cells. Therefore, our 
data suggest that the wild-type APC expression in ZnCh-treated HT29-APC cells blocks the 
ability of apigenin to induce a 0 2/M cell cycle arrest. These observations predict the 
importance of APC mutations for apigenin to induce 0 2/M cell cycle arrest and thus affect 
cell growth. 
In order to assess the effect of apigenin on the HT29-APC and HT29-GAL cells, 
different doses of apigenin at 0, 20, 30, 40, 60 and 80µM were used in these experiments. 
Our data revealed that treatment with 80µM apigenin resulted in the strongest physiological 
effect of apigenin on the inhibition of cell growth and induction of cell cycle arrest in both 
cell lines, while displaying an intermediate effect with treatments at lower doses of apigenin. 
Because the later experiments involved assessing the effect of apigenin in the presence or 
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absence of wild-type APC gene, the number of different groups increased as it involved two 
different cell lines, three different time points, in addition to the different apigenin 
treatments. Therefore, apigenin treatments were performed at 0, 40, and 80µM apigenin ( as 
indicated in results) in an effort to achieve optimal responses in the cell lines and simply the 
experimental design. Presently, no studies have reported comparisons between in vivo and in 
vitro apigenin concentrations at different doses of apigenin treatment in colon cancer cells. 
However, the cellular concentrations detected in the apigenin-treated C50 murine 
keratinocyte cultured cells at doses up to 45µM (Lepley et al., 1996) were similar to the 
concentrations revealed in the in vivo mouse epidermal cells treated topically with 5 µM 
apigenin, a cancer preventive dose (Li et al. 1996). In addition, Lepley et al. (1996) 
demonstrated that apigenin treatment at doses up to 45µM resulted in the induction of a 
reversible G2/M cell cycle arrest in C50 murine keratinocyte cells. Similarly, the apigenin-
induced G2/M cell cycle arrest at 80µM was shown to be reversible in the SW 480 human 
colon cancer cells (Wang et al., 2000), suggesting that the apigenin effect on the cells 
appeared to be cytostatic rather than cytotoxic. It should be noted that flavonoids could be 
toxic, as studies by Birt et al (1986) have shown that topical apigenin treatment at lO0µM 
induced the ornithine decarboxylase (ODC) activity, a tumor promotion marker, in the mouse 
epidermis. However, the cellular concentration with this topical dose is unknown. 
As expected, an increase in cell number with incubation time was seen when the 
HT29-GAL cells were treated with 0µM apigenin in the presence or absence of Zn Ch, since 
these cells did not express wild-type APC gene upon ZnCh treatment. Although cell 
numbers in the HT29-APC were increased after 120 hr treatment with 0µM apigenin when 
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compared to 0 hr, cell growth was not seen when these cells were treated with 0µM apigenin 
and ZnCh. This observed cell growth inhibition in the HT29-APC cells was apparently due 
to the induction of apoptosis in the HT29-APC cells following ZnCh treatment (induction of 
wild-type APC expression) as shown in our TUNEL assay results. It is noteworthy that the 
decrease in HT29-APC cells was more prominent than the decrease in HT29-GAL cells 
when treated with 80µM apigenin and 1 00µM Zn Ch. Evidently, the decrease in the HT29-
GAL cells correlated with the apigenin-induced G2/M cell cycle arrest demonstrated earlier, 
as the ZnCh-treated HT29-GAL cells did not reveal an increase in apoptosis. However, the 
HT29-APC cells were not blocked at G2/M cell cycle phase when treated with 80µM 
apigenin and 1 00µM Zn Therefore, the decrease in HT29-APC cell growth was due, in 
part, to the induction of apoptosis (induction of wild-type APC gene expression) following 
treatment with 80µM apigenin and 1 00µM Zn Ch. Interestingly, the HT29-APC cells 
revealed higher percentage of apoptotic cells when treated with 80µM apigenin and ZnCh 
compared to 0µM apigenin and This data suggest that the apigenin-treated HT29-
APC cells appeared to have enhanced apoptosis induction when expressing wild-type APC 
(following treatment of ZnCh). It should be noted, however, that the induction of the 
expression of wild-type APC together with the apigenin treatment might have affected other 
cellular regulatory pathways in the HT29-APC cells. 
The efficacy of dietary apigenin on chemoprevention of colon carcinogenesis was 
investigated through a dietary approach in the Min mouse model (Au et al. unpublished). 
Min mice have been widely used to study colon carcinogenesis because they are transfected 
with APC mutations in chromosome 18 (codon 850), which will enable them to 
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spontaneously develop large number of intestinal polyps. These lesions are reminiscent of 
familial adenomatous polyposis (F AP) (Shoemaker et al. 1997). Our results suggest that 
apigenin might be effective in reducing the genetically-induced tumors in the Min mouse 
model. However, unpublished findings (Au et al.) revealed that apigenin failed to reduce the 
genetically-induced tumors, this result may be due to the low doses of apigenin that were 
used in the diet. Further, it must be noted that, unlike human colon cancer, the majority of 
the adenomas in the min mice were located in the small intestine, and there were none or 
only a few adenomas found in the colon. Finally, the apparent discrepancy between the cell 
culture and the min mice experiments may be explained by the different location of the APC 
mutation in the Min mice ( chromosome 18) and in the HT29 human colon cancer cell line 
( chromosome 5q21 ). Therefore, future studies involving other mouse models that better 
simulate human colon tumors will be required to determine the effectiveness of apigenin in 
colon carcinogenesis. 
In conclusion, our results show that apigenin induced cell growth inhibition by 
blocking cell cycle progression at Gz/M phase in the HT29-APC and HT29-GAL cells. 
Wild-type APC gene expression in the zinc-induced HT29-APC cells was associated with the 
inability of apigenin to induce a G2/M cell cycle arrest, suggesting that apigenin may be more 
effective in inducing G2/M arrest in cells with APC mutations. 
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Figurel. Impact of Apigenin on HT29-APC and HT29-GAL cell numbers. Cells were 
treated with different doses of apigenm up to 48hr and counted using a 
hemocytometer (Mean+ SD; n=4). Different letters within each cell line indicated a 
significant difference in cell count. Statistical analysis (ANOVA with Tuk:ey's 
multiple comparison test) indicated a significant decrease in cell count in HT29-
APC and HT29-GAL cells when treated with increamental doses of apigenm. (b<a, 
P<0.05 and d<c, P<0.05) 
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Figure 2. Impact of Apigenin on HT29-APC and HT-29-GAL cell cycle arrest. Cells were 
cultured in media with different doses of apigenin (0-80 µM) for 48 hours, and the 
cell cycle was monitored by DNA flow cytometric analysis. Means±SD from three 
independent experiments are shown. Different letters within each treatment 
indicated a significant difference in percent of G2/M cells for each cell line. 
Statistical analysis (ANOV A with Tukey's multiple comparison test) indicated a 
significant increase in percent of G2/M cells in HT29-APC and HT29-GAL cells 
when treated with increamental doses of apigenin. (a<b, P<0.05 and c<d, P<0.05) 
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Figure 3. Impact of Apigenin and ZnCh (induction of wild-type APC in HT29-APC) on 
HT29-APC and HT-29-GAL cell numbers. HT29-APC and HT29-GAL cells were 
cultured and treated with apigenin (0, 40 and 80µM) and/or with ZnCl2 (lO0µM) 
for up to 120 hr. Means±SD from six independent experiments are shown. Data 
were analyzed by ANOVA with Tukey's multiple comparison test. Different letters 
within each treatment indicated a significant difference in cell number for each cell 
line. Data without letters were not significantly different between the incubation 
times. The slope in the HT29-APC cells (80µM+Zn treatment) was greater than the 
HT29-GAL cells upon similar treatment (P<0.05). (a<b<c, P<0.05; e<d, P<0.05; 
g< f, P<0.05; h<i<j, P<0.05; l<k, P<0.05; m<n<o, P<0.05; q<p, P<0.05) 
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Figure 4. Impact of Apigenin and Zn Ch (induction of wild-type APC in HT29-APC) on 
HT29-APC and HT-29-GAL cell cycle arrest. HT29-APC and HT29-GAL cells 
were cultured and treated with apigenin (0 and 80µM) and/or with ZnC1i (l00µM) 
for up to 120 hr. Means±SD from three independent experiments are shown. Data 
were analyzed by ANOVA with Tukey's multiple comparison test. Different letters 
within each treatment indicated a significant difference in percentage of G2/M cells 
for each cell line. Data without letters were not significantly different between the 
incubation times (a<b, P<0.05; c<d, P<0.05; e<f, P<0.05). 
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Figure 5. Induction of apoptosis (upon addition of ZnCh) on apigenin-treated HT29-APC and 
HT29-GAL cells. HT29-APC and HT29-GAL cells were cultured in media with 
apigenin (0 and 80µM) and the presence or absence ofZnCl2 (lO0µM) for up to 
120 hr. Means±SD from three independent experiments are shown. Data were 
analyzed by ANOVA with Tukey's multiple comparison test. Different letters 
within each treatment indicated a significant difference in percentage of apoptotic 
cells for each cell line. Data without letters were not significantly different between 
the incubation times. The HT29-APC cells treated with 80µM+ ZnCl2 presented a 
greater slope compared to 0µM ZnCl2 treatment (P<0.03). (a<b<c, P<0.05; d<e<f, 
P<0.05). 
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CHAPTER 3. GENERAL CONCLUSIONS 
This study investigated the importance of the APC tumor suppressor gene mutations 
in relation to the effectiveness of apigenin in inducing a G2/M cell cycle arrest in human 
colon cancer cells. The hypothesis of this study was that apigenin would induce a G2/M cell 
cycle arrest in colon cancer cells with APC mutations. This hypothesis was proposed based 
on the implication that apigenin may have a stronger effect on tumors with certain genetic 
mutations (Wang et al., 2000). In order to test this hypothesis, we used the cell model system 
consisting oftransfected HT29 (HT29-APC and HT29-GAL) human colon cancer cell lines 
mentioned earlier in Chapter one. The rationale behind using the cell model system in this 
study was that it allowed the induction of the wild-type APC gene expression (with the 
addition of l00µM ZnCh) in the HT29-APC cells, normalizing the function of the full-length 
APC protein expression in HT29-APC cells verified by western blot analysis (Morin et al. 
1996). The HT29-GAL cells served as the control, containing a galactosidase plasmid. 
Thus, these cells would allow us to determine the effect of apigenin in the presence or 
absence of the inducible wild-type APC gene. Our data demonstrated in Chapter two 
confirmed our proposed hypothesis, where apigenin induced a strong inhibitory effect on the 
HT29-GAL cells in presence or absence of Zn Ch treatment. On the other hand, the presence 
of the wild-type APC gene (following treatment with ZnCh) in the apigenin-treated HT29-
APC cells appeared to block the effect of apigenin, which was anticipated in our hypothesis. 
Previously, He et al. (1998) used this cell model system to identify the Tcf-regulated 
genes involved in the wnt-1 signaling pathway. The presence of the wild-type APC gene in 
the HT29-APC cells reduced the activity of the c-myc proto-oncogene (He et al. 1998). 
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Therefore, it was suggested that the APC tumor supressor gene might modulate the 
transcription of c-myc pro.to-oncogene. The APC tumor suppressor gene may directly 
modulate the transcription of the proto-oncogene c-myc, whereas the mutations of the APC 
tumor ·suppressor gene led to the induction and over-expression of the c-myc oncogene 
expression (He et al. 1998). · 
In considering this cell model, however, it must be noted that the transfected HT29-
APC cells derived from the HT29 human colon cancer cells. The HT29 cells contain APC 
gene mutations on chromosome 5q21, as well as a mutuated p53 gene and a wild-type ras 
(Huang et al. 1994). As a result, the induction of the wild-type APC gene in the HT29-APC 
cells did not eliminate the APC and the p53 gene mutations. The wild-type APC expression 
presumably corrected the deficit in APC function in the HT29-APC cells. Therefore, this 
issue was important to consider when interpreting the data in the present study on the role of 
the presence of the wild-type APC gene in relation to the effectiveness of apigenin to induce 
cell cycle arrest in colon tumor cells. 
It was crucial to determine the time period required for the induction of the wild-type 
APC gene in the HT29-APC cells, which was manifested by an increase in apoptosis in the 
ZnCh-treated HT29-APC cells. We faced the potential problem that the time period required 
to induce apoptosis in the HT29-APC cells (induction of wild-type APC expression) might 
occur before the effect of apigenin on cell cycle arrest is observed in these cells, thus 
affecting the cell cycle arrest data interpretation. Therefore, TUNEL assay was performed to 
assess the induction of apoptosis in the Zn Ch-treated HT29-APC cells (induction of wild-
type APC expression) with incubation time up to 120 hr, in order to conduct the experiments 
involving treatments with apigenin and/or ZnCh. The TUNEL assay results shown in 
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Chapter two revealed a moderate increase and a more striking increase in apoptosis at 48hr 
and 120hr, respectively, after treatment with ZnCh in the HT29-APC cells. Therefore, this 
time frame was adequate for our experiments with apigenin and ZnCh treatment, as the 
G2/M cell cycle arrest was observed at 48hr after treatment with apigenin. 
Interestingly, the HT29-APC cells revealed a higher percentage of apoptotic cells 
when treated with 80µM apigenin and ZnCh compared to 0µM apigenin and ZnCh, which 
was not anticipated in our hypothesis. The HT29-GAL cells, serving as a control for the 
effect of zinc, showed no changes in apoptosis when treated with zinc. It is also noteworthy 
that the decrease in HT29-APC cells was more prominent when treated with 80µM apigenin 
and 1 00µM Zn Ch compared to the treatment with 0µM apigenin and 1 00µM Zn Ch, which 
paralleled the observed TUNEL assay results. While it appeared that apigenin may have 
enhanced the sensitivity of the HT29-APC cells to apoptosis when expressing the wild-type 
APC gene (following treatment ofZnCh), these data suggested that the treatment of both 
apigenin and ZnCh may have triggered other cellular regulatory pathways. 
Because the cell model system applied in this study proved useful to investigate the 
effect of apigenin in presence or absence of the wild-type APC gene, future studies may 
involve looking into other similar cell model systems with different inducible genes such as 
ras and p53. These :findings may contribute significantly to the better understanding of the 
role of dietary factors in relation to the tumors with different mutations. In addition, it may 
also be speculated that other flavonoids found in plant foods would have a similar inhibitory 
effect as apigenin on the human colon cancer cells. The normalization of certain cellular 
functions, which are absent in tumors, would be expected to block the inhibitory effect of the 
flavonoids. Therefore, patients with certain genetic susceptibilities to colon cancer such as 
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FAP (familial adenomatous polyposis) would certainly benefit of the potential 
chemoprevention suggested through the consumption of a diet rich in fruits and vegetables. 
In conclusion, we proved our proposed hypothesis showing that apigenin induced cell 
growth inhibition by blocking cell cycle progression at G2/M phase in the HT29-APC and 
HT29-GAL cells. As expected, the wild-type APC gene expression in the ZnCh-induced 
HT29-APC cells was associated with the inability of apigenin to induce a G2/M cell cycle 
arrest. The HT29-GAL cells revealed an apigenin-induced G2/M cell cycle arrest, regardless 
of the presence of Zn Ch, since they did not express wild-type APC expression. Therefore, 
our data suggest that apigenin appeared to be more effective in inducing G2/M cell cycle 
arrest in tumors with APC mutations. These findings promise to yield new insights into how 
dietary factors may help prevent colon cancer in patients with certain genetic susceptibility. 
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